Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Abstract 


Candida albicans is a component of the normal flora of the alimentary tract and also is found on the mucocutaneous membranes of the healthy host. Candida is the leading cause of invasive fungal disease in premature infants, diabetics, and surgical patients, and of oropharyngeal disease in AIDS patients. As the induction of cell-mediated immunity to Candida is of critical importance in host defense, we sought to determine whether human dendritic cells (DC) could phagocytose and degrade Candida and subsequently present Candida antigens to T cells. Immature DC obtained by culture of human monocytes in the presence of granulocyte-macrophage colony-stimulating factor and interleukin-4 phagocytosed unopsonized Candida in a time-dependent manner, and phagocytosis was not enhanced by opsonization of Candida in serum. Like macrophages (Mphi), DC recognized Candida by the mannose-fucose receptor. Upon ingestion, DC killed Candida as efficiently as human Mphi, and fungicidal activity was not enhanced by the presence of fresh serum. Although phagocytosis of Candida by DC stimulated the production of superoxide anion, inhibitors of the respiratory burst (or NO production) did not inhibit killing of Candida, even when phagocytosis was blocked by preincubation of DC with cytochalasin D. Further, although apparently only modest phagolysosomal fusion occurred upon DC phagocytosis of Candida, killing of Candida under anaerobic conditions was almost equivalent to killing under aerobic conditions. Finally, DC stimulated Candida-specific lymphocyte proliferation in a concentration-dependent manner after phagocytosis of both viable and heat-killed Candida cells. These data suggest that, in vivo, such interactions between DC and C. albicans may facilitate the induction of cell-mediated immunity.

Free full text 


Logo of iaiLink to Publisher's site
Infect Immun. 2001 Nov; 69(11): 6813–6822.
PMCID: PMC100059
PMID: 11598054

Candida albicans Is Phagocytosed, Killed, and Processed for Antigen Presentation by Human Dendritic Cells

Editor: R. N. Moore

Abstract

Candida albicans is a component of the normal flora of the alimentary tract and also is found on the mucocutaneous membranes of the healthy host. Candida is the leading cause of invasive fungal disease in premature infants, diabetics, and surgical patients, and of oropharyngeal disease in AIDS patients. As the induction of cell-mediated immunity to Candida is of critical importance in host defense, we sought to determine whether human dendritic cells (DC) could phagocytose and degrade Candida and subsequently present Candida antigens to T cells. Immature DC obtained by culture of human monocytes in the presence of granulocyte-macrophage colony-stimulating factor and interleukin-4 phagocytosed unopsonized Candida in a time-dependent manner, and phagocytosis was not enhanced by opsonization of Candida in serum. Like macrophages (M[var phi]), DC recognized Candida by the mannose-fucose receptor. Upon ingestion, DC killed Candida as efficiently as human M[var phi], and fungicidal activity was not enhanced by the presence of fresh serum. Although phagocytosis of Candida by DC stimulated the production of superoxide anion, inhibitors of the respiratory burst (or NO production) did not inhibit killing of Candida, even when phagocytosis was blocked by preincubation of DC with cytochalasin D. Further, although apparently only modest phagolysosomal fusion occurred upon DC phagocytosis of Candida, killing of Candida under anaerobic conditions was almost equivalent to killing under aerobic conditions. Finally, DC stimulated Candida-specific lymphocyte proliferation in a concentration-dependent manner after phagocytosis of both viable and heat-killed Candida cells. These data suggest that, in vivo, such interactions between DC and C. albicans may facilitate the induction of cell-mediated immunity.

Candida albicans is a component of the normal microflora of the alimentary tract and mucocutaneous membranes of the healthy host. However, when immune defenses are compromised or the normal microflora balance is disrupted, Candida transforms itself into an opportunistic pathogenic killer. Indeed, dissemination of Candida is the leading cause of invasive fungal disease in premature infants, diabetics, and surgical patients and of oropharyngeal disease in AIDS patients (2, 9, 15, 20, 28, 34, 45, 61, 79). Despite appropriate therapy, mortality from systemic Candida infections in immunocompromised individuals is nearly 30% (82). In human immunodeficiency virus-infected individuals who have not yet developed advanced immunodeficiency, the prevalence of oropharyngeal Candida is from 7 to 48% of patients (33). As the immunodeficiency in AIDS patients progresses, the prevalence of oral candidiasis increases to 43 to 93% (59). Furthermore, the development of oral candidiasis in the early stages of human immunodeficiency virus infection is highly predictive of worsening immunodeficiency.

Host resistance against infections with C. albicans is mediated predominantly by neutrophils and macrophages (M[var phi]). During the induction of cell-mediated immunity (CMI), Candida antigens are presented to T cells and stimulate their proliferation with subsequent cytokine synthesis, and in both humans and mice these cytokines enhance the candidacidal functions of the phagocytic cells (3, 18, 26, 46). In systemic candidiasis in mice, cytokine production has been found to be a function of CD4+ T helper (Th) cells. The Th1 response, characterized by the production of interleukin-2 (IL-2), IL-12, gamma interferon (IFN-γ), and tumor necrosis factor alpha (TNF-α), is associated with M[var phi] activation and enhanced resistance against reinfection. The Th2 response, which produces IL-4, IL-6, and IL-10, is linked with the development of chronic disease (10, 11, 60, 64, 65, 67). However, while it is generally accepted that production of Th1 cytokines is important for M[var phi] activation and clearance of the fungus, recent studies suggest that a critical balance of both Th1 and Th2 cytokines is necessary to develop protective immunity (48, 49, 66). Furthermore, the balance of Th1 and Th2 cytokines produced depends on the model of candidiasis being studied.

Although M[var phi] can serve as antigen-presenting cells (APC), dendritic cells (DC) are more potent antigen presenters than M[var phi] (70). DC precursors originate in the bone marrow, enter the blood, and seed nonlymphoid tissues. These DC are classified as immature and are specialized in antigen uptake and processing (5). The immature DC differentiate into mature DC as they migrate to tissue-draining secondary lymphoid organs, where they efficiently present antigen to T cells (4, 14, 42, 54, 63, 68). The strategic location of DC in tissues, on mucosal surfaces, and in the skin suggests that these cells are in a prime position to initiate protective immune responses against Candida.

For these adaptive immune responses to occur, the DC either would have to take up soluble fungal antigens or phagocytose the fungus themselves. If the latter occurs, it would require not only uptake of the fungus but also killing, degradation, and processing of fungal antigens. Teleologically, it would seem to be more efficient if the DC ingested the Candida rather than their having to wait for antigens to be shed or regurgitated by other immune cells such as M[var phi]. Recently, we demonstrated that immature human DC were able to phagocytose, kill, and degrade the fungal pathogen Histoplasma capsulatum (24). Furthermore, the DC were able to process H. capsulatum antigens and stimulate T-cell proliferation.

Human and mouse M[var phi] bind and internalize Candida cells via the mannose-fucose receptor (MFR) (37, 47). As human DC and Langerhans cells also express the MFR on their surface (6, 13), we hypothesized that immature DC might phagocytose Candida through the MFR and subsequently kill the organism, process Candida-specific antigens, and stimulate lymphocyte proliferation.

Most recently it was reported that mouse DC phagocytose and kill Candida and that recognition was through the MFR (19). The data presented herein confirm these observations for human DC and also demonstrate two important differences in the interaction of human and mouse DC with Candida. The first is that human and mouse DC apparently kill Candida by different mechanisms. The second difference is that Candida-infected human DC stimulate T-cell proliferation without the requirement for the addition of exogenous IL-2.

MATERIALS AND METHODS

Reagents.

NG-monomethyl-l-arginine (NMMA) was purchased from Calbiochem, La Jolla, Calif. Fluorescein isothiocyanate (FITC), type III ferricytochrome c, NG-nitro-l-arginine methyl ester (NAME), superoxide dismutase (SOD), catalase, mannitol, cytochalasin D (CD), l-fucose, galactose, N-acetyl-d-glucosamine, d-glucosamine, α-methyl-d-mannoside, mannosylated bovine serum albumin (BSA), and d-mannose were purchased from Sigma, St. Louis, Mo. Diphenylene iodonium bisulfate (DPI) was a gift of Andrew Cross, The Scripps Research Institute, La Jolla, Calif. A 1 mM stock concentration of DPI was prepared in dimethyl sulfoxide (DMSO) and stored at −80°C. DPI was diluted into RPMI 1640 (Gibco-BRL, Gaithersburg, Md.) to the desired concentration just before use. CD was dissolved in DMSO at a concentration of 1 mg/ml, and aliquots were stored at −80°C until use. Cytochrome c (1 mM) was dissolved in Krebs-Ringer phosphate buffer containing 0.2% dextrose and stored at −20°C. All other reagents were prepared in RPMI 1640 and sterile filtered. Pooled human serum (PHS) prepared from six to eight individual donors was pooled and stored in 200-μl aliquots at −80°C until use.

Preparation of human DC and M[var phi].

Monocytes were isolated by sequential centrifugation on Ficoll-Hypaque and Percoll gradients (Amersham Pharmacia LKB, Piscataway, N.J.) from buffy coats obtained from the Hoxworth Blood Center, Cincinnati, Ohio, or from blood drawn from normal adult donors in our laboratory (52). To obtain DC, monocytes were cultured in 6-well tissue culture plates (Corning-Costar, Cambridge, Mass.) at 6 × 105/ml in RPMI 1640 containing 200 mM glutamine, 50 μM 2-mercaptoethanol (Sigma), 10% heat-inactivated fetal calf serum (FCS; Gibco-BRL), 50 ng of kanamycin (Sigma)/ml, 1% nonessential amino acids (BioWhittaker, Walkersville, Md.), and 1% pyruvate (BioWhittaker). Human recombinant granulocyte-M[var phi] colony-stimulating factor (115 ng/ml; Peprotech, Inc., Rocky Hill, N.J.) and human recombinant IL-4 (rIL-4; 50 ng/ml; Peprotech, Inc.) also were added to each well, and DC were studied after 6 to 8 days of culture.

M[var phi] were obtained by culture of monocytes at 1 × 106/ml in Teflon beakers with RPMI 1640 containing 15% PHS, 10 μg of gentamicin (Sigma)/ml, 100 U of penicillin/ml, and 100 μg of streptomycin (Sigma)/ml (52). M[var phi] were studied after 5 to 7 days in culture.

Fluorescence-activated cell sorter (FACS) analysis.

DC (5 × 105) were incubated with primary monoclonal antibodies (MAbs) at 4°C for 45 min. After two washes in phosphate-buffered saline (PBS) containing 1% BSA (PBS-BSA), the cells either were fixed in 1% paraformaldehyde or were incubated with a fluorochrome-labeled secondary antibody for an additional 45 min at 4°C. The cells then were washed twice with PBS-BSA and fixed overnight with 1% paraformaldehyde before analysis by flow cytometry on a FACScalibur flow cytometer (Becton Dickinson, San Jose, Calif.) with standard optics and filter. The acquired data were analyzed with CELLQuest software (Becton Dickinson). Nonspecific antibody binding was blocked by preincubation of DC with 250 μg of human immunoglobulin G (IgG) (Sigma) per ml for 30 min at 4°C prior to the addition of primary MAb. The following MAbs were used: FITC-labeled CD11a, CD11b, CD11c, CD80, CD18, CD14, CD40, and mouse IgG1, IgG2a, and IgM (Ancell, Bayport, Maine); unconjugated CD19, CD3, CD16, and goat anti-mouse IgG and IgM (Ancell); CD83 (Serotec, Raleigh, N.C.); CD86 (Pharmingen, San Diego, Calif.); HLA-DR (CAL-Tag, South San Francisco, Calif.); CD1a (Biosource International, Menlo Park, Calif.); and CD56 (Tcell Diagnostics, Inc., Woburn, Mass.). The DC expressed high levels of CD18, CD11b, CD11c, HLA-DR, and VLA-5 and moderate levels of CD11a, CD1a, and CD86. DC were negative for M[var phi], T-cell, B-cell, and NK markers (24).

C. albicans.

Candida (ATCC 18804) was maintained on Sabouraud dextrose agar (Difco Laboratories, Detroit, Mich.). Yeast cells were grown for 16 h in Sabouraud dextrose broth at 30°C with orbital shaking at 150 rpm. For binding and phagocytosis assays, yeast cells were harvested by centrifugation, washed three times in 0.01 M phosphate buffer (pH 7.2) containing 0.15 M NaCl (PBS) and then heat-killed (HK) at 65°C for 1 h. Yeast cells were stored at 4°C in PBS containing 0.05% sodium azide. To label cells with fluorescein, HK yeast cells were resuspended to 2 × 108/ml in either 0.01 mg of FITC/ml (suspension assays) or 0.1 mg of FITC/ml (M[var phi] Terasaki plate binding assay) in 0.05 M carbonate-bicarbonate buffer (pH 9.5). After incubation for 15 min at room temperature in the dark, FITC-labeled Candida cells were washed twice with Hanks balanced salt solution containing 0.25% BSA (HBSA) and resuspended to the appropriate concentration in HBSA.

For studies with viable yeast cells, overnight cultures were harvested by centrifugation, washed thee times in HBSA, and resuspended to 50 ml in HBSA. The yeast cells were counted on a hemacytometer and standardized to the appropriate concentration according to the assay protocol.

Phagocytosis assay.

Phagocytosis of Candida by human DC and M[var phi] was quantified as described previously for H. capsulatum (52). HK Candida cells were opsonized in 5% PHS at 2 × 108 yeast cells/ml for 20 min at 37°C. After washing twice in HBSA, opsonized Candida cells were resuspended in HBSA. DC were harvested from 6-well plates, and M[var phi] were harvested from beakers after 5 to 7 days of culture, washed in HBSA, and standardized to 2 × 106 /ml. DC or M[var phi] (1 × 106) were incubated with opsonized or unopsonized FITC-labeled HK Candida cells (5 × 106) in a total volume of 1 ml at 37°C in a water bath with orbital shaking at 150 rpm for various periods of time. At the end of the incubation period, trypan blue (1 mg/ml in PBS) was added for 15 min at 25°C to quench the fluorescence of bound but uningested organisms (52). The cells then were washed with HBSA, cytocentrifuged onto glass slides, and fixed in 1% paraformaldehyde at 4°C. Coverslips were mounted in 90% glycerol in PBS, and phagocytosis was quantified by phase-contrast and fluorescence microscopy. A total of 100 cells were counted per slide and the number of ingested or bound but uningested yeast cells was determined. Results are expressed as the mean ± standard error of the mean (SEM) of the phagocytic index (PI) (the total number of yeast cells ingested per 100 DC or M[var phi]) and as the percent ingestion (the percentage of DC or M[var phi] containing one or more yeast cells).

Binding assays.

DC and M[var phi] were harvested after 5 to 7 days of culture, washed, and resuspended to 4 × 106/ml in HBSA. Fifty microliters of DC were incubated in 12- by 75-mm polypropylene tubes for 30 min at 37°C with various sugars or HBSA only. Fifty microliters of FITC-labeled Candida cells (2 × 107/ml) then were added to each tube and incubated for 20 min at 37°C in a water bath with orbital shaking at 150 rpm. Ten microliters of sample then was mounted on a clean glass slide and coverslipped for immediate quantitation via phase-contrast and fluorescence microscopy. One hundred DC were counted per slide, and the results are expressed as the mean ± SEM of the attachment index (the total number of organisms bound per 100 cells).

For binding assays with M[var phi], the cells (2.5 × 103) were allowed to adhere for 1 h at 37°C in 5% CO2–95% air in the wells of a Terasaki tissue culture plate (Miles Scientific Division, Naperville, Ill.) that previously had been coated with 1% human serum albumin. The cells were washed twice with HBSA and then incubated with various sugars or HBSA for 30 min at 37°C. Five microliters of FITC-labeled HK Candida cells (2 × 107/ml) then was added to each well and the mixture was incubated for 20 min at 37°C. Unbound organisms were removed by washing with HBSA and the monolayers were fixed with 1% paraformaldehyde. Attachment of the yeast cells was quantified via fluorescence microscopy on an inverted microscope (Diaphot; Nikon Inc. Instrument Group, Melville, N.Y.) by counting 100 M[var phi] per well. Results are expressed as mean ± SEM of the attachment index (52).

Quantitation of DC and M[var phi] fungicidal activity.

DC and M[var phi] (5 × 105) were incubated with Candida cells (5 × 104) in the presence or absence of 10% PHS in polypropylene tubes for 1, 2, or 4 h at 37°C in a water bath with orbital shaking at 150 rpm. At each time point, the cells and yeast cells were centrifuged, the supernatant was aspirated, and the mixtures were resuspended in 1 ml of sterile water. The contents then were vortexed vigorously prior to serial dilution and plating on Sabouraud dextrose agar plates. Inspection of the lysate by light microscopy confirmed that the yeast cells were not clumped. After incubation at 30°C for 48 h, CFU were counted and the percent Candida cells that were killed was calculated by comparison with the CFU obtained from the original inoculum. Some experiments were performed under anaerobic conditions in a Forma Scientific (model 1024; Marietta, Ohio) anaerobic chamber.

Quantitation of PL fusion.

DC (1 × 106) were incubated for 2 h at 37°C in M199 (Gibco-BRL) containing 10% human serum, 10 μg of gentamicin/ml, and 18-nm-diameter colloidal gold beads stabilized with horseradish peroxidase (HRP:Au18) (53). The DC were washed thee times with medium and then incubated an additional 2 h at 37°C to ensure that the HRP:Au18 entered the lysosomal compartments. After the second incubation, 1 × 106 viable Candida cells were added and phagocytosis was allowed to proceed for 1 h at 37°C. After 1 h the DC were washed three times with ice-cold 0.1 M sodium cacodylate buffer (pH 7.4) and then processed for electron microscopy. DC phagolysosomal fusion (PL fusion) was quantified by counting the number of 18-nm gold particles in phagosomes containing Candida (53). The data are expressed as the mean ± SEM of the number of gold particles per yeast-containing phagosome. H. capsulatum and Saccharomyces cerevisiae also were studied for comparison.

Quantitation of superoxide anion (O2) production.

O2 generation by DC and M[var phi] was quantified as the SOD-inhibitable reduction of ferricytochrome c (type III; Sigma) as described previously (69). DC and M[var phi] (2 × 106) were incubated for 1 h at 37°C with opsonized or unopsonized Candida cells (1 × 107) in Krebs-Ringer phosphate buffer with 0.2% dextrose containing 80 μM cytochrome c. Control wells contained cytochrome c without Candida (resting cells) or the Candida plus 40 μg of SOD/ml. At the end of the incubation, the supernates were collected by centrifugation at 4°C. The absorbance of the supernates at 550 nm was measured in a Spectronic Genesys 5 (Milton Roy, Rochester, N.Y.), and the background absorbance in control tubes containing only buffer and cytochrome c was subtracted. All experiments were performed in triplicate and results were calculated as nanomoles of O2 using E550 = 2.1 × 104 M−1 cm−1. Results are expressed as nanomoles of cytochrome c reduced per 2 × 106 cells per hour.

T-cell isolation.

At day 6 of the DC culture, blood was obtained from the same donor, and mixed mononuclear cells were isolated on Ficoll-Hypaque gradients (52). The mononuclear cells were standardized to 7.5 × 107/ml in RPMI 1640 containing 5% FCS and 10 μg of gentamicin/ml, warmed to 37°C, and passed over a nylon wool column at 37°C. After 1 h of incubation on the column, the first 15 ml of column flowthrough was collected and cultured at 2 × 106/ml overnight in a T flask (Corning-Costar). After 24 h of culture, the nonadherent cells were collected, washed in Dulbecco's PBS (DPBS) containing 2% FCS, and incubated for 1 h on ice with mouse MAbs to human CD56 (Becton Dickinson) and human CD16 (Medarex, Annandale, Calif.) to eliminate any remaining NK cells. The cells then were washed in DPBS containing 2% FCS and incubated for 1 h at 4°C on a rocking shaker (Thermolyne, Dubuque, Iowa) with goat anti-mouse IgG magnetic beads (Perseptive Biosystems, Framingham, Mass.) at 10 beads per cell. Purified T cells were obtained after incubation of the cell-bead suspension on a Dynal MPC-1 magnet (Oslo, Norway) for 10 min. The T cells remaining in suspension were collected and used in the antigen presentation assays as described below. T cells were 98.5% CD3+ by FACS analysis (24).

Antigen presentation assays.

Antigen presentation by DC to T cells was quantified by the incorporation of [3H]thymidine (24). DC were incubated with either HK or viable Candida cells for 1 h at 37°C in a 96-well plate to allow for phagocytosis of the yeast cells. Autologous T cells then were added to each well and the plate was cultured at 37°C for 7 days. In these experiments, the media contained 10% autologous serum rather than PHS. In wells containing viable Candida cells, amphotericin B (1.25 μg/ml) was added after the first 48 h of culture to prevent overgrowth of the yeast cells. On day 7 of culture, 1.0 μCi of [3H]thymidine (specific activity, 6.7 Ci/mmol; Dupont-New England Nuclear) in RPMI 1640 was added to each well. After further incubation for 24 h at 37°C, the contents of the wells were harvested onto glass fiber filters and counts per minute were determined in a liquid scintillation counter. The results are expressed as the mean ± SEM of the counts per minute incorporated by T cells in the presence of various amounts of DC and Candida. DC and T cells were greater than 95% viable on all days of culture, as determined by trypan blue dye exclusion.

Statistics.

Statistical analysis of the data was performed using Sigma Stat (Jandel Scientific, San Rafael, Calif.). Student's t test or the Mann-Whitney rank sum test was used to analyze the data for statistical significance, and results were considered significant at a P level of <0.05.

RESULTS

Phagocytosis and killing of C. albicans by human DC.

Previously, we have demonstrated that immature human DC phagocytose and kill H. capsulatum (24), and others have shown that immature human DC can phagocytose some bacteria and protozoa (1, 21, 32, 78). Therefore, we first examined the ability of human DC to phagocytose Candida and compared their phagocytic activity to human monocyte-derived M[var phi]. DC and M[var phi] were incubated in suspension with unopsonized FITC-labeled HK Candida for various periods of time, and phagocytosis was quantified as described in Materials and Methods. Figure Figure11 shows that DC ingested Candida in a time-dependent manner. Phagocytosis was evident as early as 10 min, and after 1 h almost 60% of DC had ingested at least 1 Candida yeast cell, with an average of over 5 yeast cells per DC. Opsonization of the yeast cells did not enhance DC phagocytosis of Candida (Table (Table1)1) nor did it affect the percentage of DC-associated yeast cells that were ingested (61% for unopsonized yeast cells and 58% for opsonized yeast cells).

An external file that holds a picture, illustration, etc.
Object name is ii1110400001.jpg

Human DC phagocytose C. albicans in a time-dependent manner. DC or M[var phi] (2 × 106) were incubated with unopsonized FITC-labeled Candida (1 × 107) for various periods of time. At the end of each time period 1 mg of trypan blue/ml was added to each sample for 15 min to quench the fluorescence of uningested organisms. An aliquot of cells was cytocentrifuged onto glass slides and phagocytosis was quantified by phase and fluorescence microscopy. The data are presented as the percent ingesting (percent DC or M[var phi] containing at least one ingested organism) and the phagocytic index (the total number of organisms ingested/100 DC or M[var phi]). The data are the mean ± SEM of four experiments with different donors.

TABLE 1

DC phagocytosis of C. albicans is not enhanced by seruma

Treatment% IngestionbPIcNo. of bound but uningested Candida/100 DC
No serum57 ± 3314 ± 87202 ± 58
5% PHS60 ± 5230 ± 70164 ± 51
aDC were incubated with Candida in the presence or absence of 5% PHS for 1 h at 37°C. Phagocytosis was quantified by phase-contrast and fluorescence microscopy. Data are the mean ± SEM of three experiments performed in duplicate. 
bPercentage of DC ingesting 1 or more Candida cells. 
cNumber of Candida cells ingested per 100 DC. 

To determine if ingested Candida cells were killed by DC, DC and M[var phi] were incubated with viable Candida cells in the presence or absence of 10% PHS for 1, 2, and 4 h at 37°C. The data in Fig. Fig.22 demonstrate that over the 4-h incubation period, both DC and M[var phi] were equally efficient at killing Candida, and fungicidal activities were equivalent regardless of whether or not PHS was present to opsonize the yeast cells.

An external file that holds a picture, illustration, etc.
Object name is ii1110400002.jpg

Human DC kill C. albicans as well as M[var phi]. Viable Candida (5 × 104) were incubated with DC or M[var phi] (5 × 105) in the presence or absence of 5% PHS in suspension for 1, 2, and 4 h at 37°C. At each time point, remaining CFU were quantified as described in Materials and Methods. The data are the mean ± SEM of five experiments.

Binding of Candida cells to human DC is mediated by the MFR.

Our original rationale for these experiments was based on the fact that DC contain high levels of the MFR on their surface (6, 13). As M[var phi] utilize the MFR to recognize and phagocytose unopsonized Candida cells (37, 47), we hypothesized that human DC MFR might perform the same function. To test this hypothesis, DC and M[var phi] were preincubated with various sugars and their subsequent capacity to bind FITC-labeled HK Candida cells was quantified. Because M[var phi] bound Candida poorly in suspension, they were studied under adherent conditions in Terasaki plates. DC or M[var phi] were preincubated with various sugars for 30 min at 37°C and then incubated with FITC-labeled Candida cells for an additional 20 min. Preincubation of DC or M[var phi] with mannose, fucose, or mannosylated BSA, but not galactose, significantly inhibited the binding of Candida, strongly suggesting that binding was mediated though the MFR (Table (Table2).2).

TABLE 2

Binding of Candida to human DC is mediated via the MFRa

Sugar and concnDC
M[var phi]
AIb (n)% InhibitioncAI (n)% Inhibitionc
None335 ± 23 (24)440 ± 38 (19)
Mannose
 50 mM31 ± 10 (3)91*298 ± 48 (3)32
 100 mM5 ± 1 (3)98*124 ± 45 (3)72
Fucose
 50 mM88 ± 35 (3)74*94 ± 21 (4)79
 100 mM2 ± 0.3 (3)99*42 ± 6 (4)90
Galactose
 100 mM405 ± 15 (3)0383 ± 107 (3)13
Mannosylated BSA
 200 μg/ml127 ± 41 (4)62*160 ± 26 (3)64
aBinding assays with DC were performed in suspension; assays with M[var phi] were performed in Terasaki trays. All assays were performed in the absence of serum. Sugars were preincubated with the cells for 30 min at 37°C, and then Candida cells were added for an additional 20 min. The data are presented as the mean ± SEM. 
bAI = attachment index, which is the number of Candida cells bound per 100 DC or M[var phi]
c*, P < 0.005 compared to untreated controls; †, P < 0.01 compared to untreated controls. 

Mechanism of DC fungicidal activity against C. albicans.

As it has long been known that polymorphonuclear cells kill Candida predominantly via the production of toxic oxygen metabolites (16, 77, 81), we next sought to determine if incubation of DC with Candida would stimulate a respiratory burst. Therefore, DC and M[var phi] were incubated for 1 h with opsonized or unopsonized C. albicans cells, and superoxide anion production was quantified by the SOD-inhibitable reduction of cytochrome c. Figure Figure33 shows that both unopsonized and opsonized Candida stimulated the release of O2 to levels roughly half that produced by M[var phi]. However, preincubation of DC or M[var phi] with either SOD (200 μg/ml), catalase (100 μg/ml), or mannitol (0.04 M) did not result in inhibition of fungicidal activity by either cell type (data not shown).

An external file that holds a picture, illustration, etc.
Object name is ii1110400003.jpg

C. albicans (Ca) stimulates human DC to produce superoxide anion. DC and M[var phi] (2 × 106) were incubated with opsonized (OP) or unopsonized Candida (1 × 107) in the absence or presence of SOD (50 μg/ml), and the production of superoxide anion was quantified by the reduction of cytochrome c. The data are the mean ± SEM of eight experiments.

Because lack of inhibition by respiratory burst inhibitors may be caused by an inability of these agents to gain entrance to the phagosome (36), we next sought to determine if DC would kill Candida in the absence of phagocytosis. The rationale was that if killing took place extracellularly, respiratory burst inhibitors might be more effective in inhibiting killing. Therefore, DC and M[var phi] were preincubated for 5 min with 2 μg of CD/ml to disrupt actin microfilaments and inhibit phagocytosis, and then killing of Candida was quantified after incubation with the yeast cells for 1 h at 37°C. The data in Table Table33 show that both DC and M[var phi] killed Candida equally well regardless of whether or not the yeast cells were ingested. Visual inspection of aliquots taken from the tubes containing CD confirmed that yeast cells remained extracellular but were still bound to DC and M[var phi]. Furthermore, in control experiments, CD did not affect the viability of Candida or its ability to germinate. In addition, extracellular killing of C. albicans occurred over a wide range of pHs. Thus, when the extracellular medium was buffered to pH 4.0, 7.2 (standard assay), 8.0, or 10.0, there was no difference in the amount of fungicidal activity exhibited by either DC or M[var phi] (data not shown).

TABLE 3

DC and M[var phi] kill C. albicans in the absence of phagocytosisa

TargetCD% Candida killed by:
DCM[var phi]
Candida84 ± 490 ± 2
Op Candida86 ± 485 ± 3
Candida+79 ± 390 ± 2
Op Candida+80 ± 477 ± 4
aDC and M[var phi] were incubated with unopsonized Candida or Candida opsonized in 5% PHS (Op Candida) in the presence or absence of 2 μg of CD/ml for 1 h at 37°C. Fungicidal activity then was quantified as described in Materials and Methods. Data are the mean ± SEM of nine experiments. 

Having demonstrated that DC and M[var phi] killed Candida yeast cells even when they remained outside the cell, we then sought to determine if inhibitors of the respiratory burst would inhibit killing of Candida. Preincubation of DC and M[var phi] with SOD, catalase, and mannitol still did not block killing of Candida by either DC or M[var phi]. We also attempted to block killing using the NO synthase inhibitors DPI (10 μM) (74), l-NMMA (1 mM) (56), and l-NAME (1 mM) (41), but these agents also were without effect (data not shown). Finally, we tested DPI and SOD in combination (Table (Table4),4), but again there was no inhibition of DC or M[var phi] fungicidal activity.

TABLE 4

Inhibitors of the respiratory burst and NO production do not block the killing of Candida even in the absence of phagocytosisa

TargetInhibitor% Candida killed by:
DCM[var phi]
CandidaNone76 ± 290 ± 3
Op CandidaNone75 ± 574 ± 5
CandidaSOD80 ± 585 ± 8
Op CandidaSOD76 ± 383 ± 2
CandidaDPI69 ± 584 ± 2
Op CandidaDPI67 ± 374 ± 1
CandidaBoth76 ± 190 ± 2
Op CandidaBoth71 ± 285 ± 0
aDC and M[var phi] were incubated with unopsonized Candida or Candida opsonized in 5% PHS (Op Candida) in the presence 2 μg of CD/ml and in the absence or presence of SOD (200 μg/ml). DPI (10 μM), or both SOD and DPI for 1 h at 37°C. Fungicidal activity then was quantified as described in Materials and Methods. Data are the mean ± SEM of two to six experiments. 

As the production of toxic oxygen radicals did not appear to be the mechanism of DC or M[var phi] fungicidal activity, we sought to determine if DC ingesting Candida exhibited significant PL fusion. DC were loaded with HRP:Au 18 and incubated with Candida, H. capsulatum, or S. cerevisiae cells for 1 h at 37°C and then processed for electron microscopy. Figure Figure44 shows that after 1 h of phagocytosis, DC containing Candida had an average of almost 4 gold particles per phagosome. In contrast, DC that had phagocytosed S. cerevisiae had less than 2 gold particles per phagosome, while DC that had ingested H. capsulatum had about 13 gold particles per phagosome.

An external file that holds a picture, illustration, etc.
Object name is ii1110400004.jpg

C. albicans (Ca) stimulates PL fusion in human DC. DC were labeled with HRP:Au18 and then incubated with Candida, H. capsulatum (Hc), or S. cerevisae (Sc) cells for 1 h at 37°C. After fixation and processing for electron microscopy, the number of gold particles in yeast-containing phagosomes was quantified. The data are presented as the mean ± SEM of gold particles per phagosome. The number above each bar denotes the number of phagosomes counted for each fungus.

Our cautious interpretation of these data is that modest PL fusion occurred upon ingestion of C. albicans by human DC, even though it was only one-third the amount of PL fusion that occurred when DC phagocytosed H. capsulatum. The question that remained unanswered was whether this amount of PL fusion was biologically significant. In other words, was it enough to kill Candida?

To address this issue and rule out a role for toxic oxygen radicals, DC and M[var phi] fungicidal activities were quantified under anaerobic conditions. DC, M[var phi], and Candida cells were equilibrated in the anaerobic chamber for 30 min prior to initiating the killing assay. The DC and M[var phi] then were incubated with opsonized and unopsonized Candida cells for 1 or 2 h and killing of Candida was quantified as described previously. The data in Table Table55 show that both DC and M[var phi] killed Candida under anaerobic conditions almost as efficiently as under aerobic conditions.

TABLE 5

M[var phi] and DC kill C. albicans under anaerobic conditionsa

TargetTime (h)% Candida killed by:
M[var phi]DC
Candida164 ± 750 ± 4
Candida273 ± 860 ± 9
Op Candida159 ± 459 ± 4
Op Candida273 ± 463 ± 11
aDC and M[var phi] were incubated with Candida in the absence or presence of 10% PHS (Op Candida) for 1 or 2 h at 37°C under anaerobic conditions. Fungicidal activity then was quantified as described in Materials and Methods. Data are the mean ± SEM of four individual experiments. 

Antigen presentation by DC.

As DC phagocytosed and killed Candida, we next tested the ability of DC to process and present Candida antigens to T cells. In preliminary experiments, we determined that the optimal concentration of DC was 104/well (data not shown). Next, DC (104) were incubated for 1 h with various concentrations of HK or viable Candida cells and then cultured for 1 week with autologous CD3+ T cells. Lymphocyte proliferation over the last 24 h was then quantified by measuring the incorporation of [3H]thymidine. As shown in Fig. Fig.5,5, T-cell proliferation was stimulated by both viable and HK cells in a concentration-dependent manner.

An external file that holds a picture, illustration, etc.
Object name is ii1110400005.jpg

DC infected with viable and HK C. albicans (Ca) cells stimulate T-cell proliferation. Aliquots of 104 DC were incubated with various concentrations of either viable or HK Candida cells for 1 h at 37°C to allow for phagocytosis. Purified CD3+ T cells (105) then were added to the wells, and the mixtures were cultured for an additional 7 days. On day 7, the wells were pulsed with [3H]thymidine to quantify T-cell proliferation. The data are presented as the mean ± SEM of the counts per minute of five experiments performed in triplicate. The counts per minute in control wells containing DC and T cells only was <2,000.

DISCUSSION

DC are the most potent APC of the immune system and are vital for the initiation of primary T-cell-mediated immune responses that are the hallmark of cell-mediated immunity (CMI) (70). As the host defense against C. albicans requires the induction of CMI, we sought to determine a role for human DC in this process. The data presented herein demonstrate that: (i) immature human DC avidly ingest Candida and that serum is not required for recognition and phagocytosis; (ii) recognition is via the MFR; (iii) DC kill Candida as efficiently as M[var phi] and do not require the presence of serum; (iv) the mechanism of DC fungicidal activity is oxygen independent; and (v) upon ingestion of viable or HK Candida cells, DC stimulate the proliferation of T cells. These data suggest that DC may play an important role in the host response to Candida infection by linking innate immunity with CMI.

In our studies of phagocytosis of Candida, we found that DC actually were slightly more phagocytic than M[var phi]. Thus, after only 1 h of incubation, 60% of DC had ingested an average of 5 unopsonized yeast cells/DC, whereas after the same incubation period less than 40% of M[var phi] had ingested an average of about 2 yeast cells/ M[var phi]. As M[var phi] are considered professional phagocytes, this counterintuitive result is most likely because of the fact that M[var phi] function better when adherent to a surface. Indeed, we used adherent M[var phi] in the binding assay because very few yeast cells bound to M[var phi] in suspension after 20 min. We observed a similar phenomenon in our studies of human DC and H. capsulatum (24).

d'Ostiani et al. (19) recently demonstrated that an immature myeloid DC line established from fetal mouse skin cells (FSDC) ingested both the yeast and hyphal forms of Candida via different mechanisms and receptors. Phagocytosis of yeast cells occurred by coiling phagocytosis characterized by the presence of overlapping bilateral pseudopods, whereas ingestion of hyphae was via the classic zipper mechanism with the formation of symmetrical pseudopods. Electron micrographs of human DC with internalized Candida cells did not reveal any evidence of coiling phagocytosis, but it was clear that the yeast cells were in membrane-bound phagosomes (data not shown). However, the earliest time point that was observed was 1 h. Not surprisingly, our data and the studies of d'Ostiani et al. (19) demonstrate that Candida cells are recognized by the MFR, as has been found for M[var phi] (37, 47).

Although original reports suggested that DC had weak or no endocytic activity (71, 72, 84), there is now considerable evidence that DC ingest numerous microbial pathogens. Mouse DC and murine-derived DC lines phagocytose bacteria such as Bordetella bronchiseptica (29, 31), Listeria monocytogenes (30), Chlamydia trachomatis (55, 75), BCG mycobacterium (35), Mycobacterium tuberculosis (76), and Salmonella enterica subsp. enterica (23), in addition to the protozoan Leishmania major (8, 39, 51, 80, 83). In vivo, murine DC containing internal Leishmania donovani (25) and L. major (50) also have been observed.

Human DC have been reported to phagocytose Borrelia burgdorferi (21), M. tuberculosis (22, 32, 43), C. trachomatis (43), L. monocytogenes (38), influenza virus (7), measles virus (27), the protozoans Trypanosoma cruzi (78) and L. donovani (1), and the fungus H. capsulatum (24). Thus, although DC are not considered professional phagocytes, they are capable of considerable phagocytic activity.

In addition to phagocytosis, human DC were found to kill Candida as efficiently as human monocyte-derived M[var phi]. Fresh complement-preserved serum did not enhance the fungicidal activities of either DC or M[var phi]. Presumably, opsonization in serum would lead to recognition and ingestion of Candida via additional receptors including the Fc receptor for IgG and complement receptor type 1 (CR1) (40, 85, 86). Thus, engagement of a variety of cell surface receptors by both cell types leads to efficient activation of the cells' microbicidal machinery.

The mechanism of DC and M[var phi] killing of C. albicans was mainly oxygen independent, probably via lysosomal hydrolases. Thus, killing was almost as efficient under anaerobic conditions as under aerobic conditions. Furthermore, PL fusion did take place in Candida-infected DC, albeit only at one-third of that observed after infection with H. capsulatum. No evidence was obtained for an oxidative killing mechanism, even though phagocytosis of Candida by DC stimulated the production of superoxide anion. Furthermore, there was no evidence that NO was involved. In contrast, murine FSDC do produce NO upon phagocytosis of Candida and hyphae, but no definitive evidence was presented to demonstrate that NO actually was responsible for killing the Candida cells (19). As our immature DC were derived from peripheral blood monocytes, these data fit in with the general idea that the preponderance of human neutrophil candidacidal activity is mediated via the production of toxic oxygen metabolites (16, 77, 81), whereas killing of Candida by human monocytes and M[var phi] occurs predominantly though nonoxidative mechanisms (17, 44, 77).

Human DC also have been reported to kill and degrade L. monocytogenes (38). In contrast, T. cruzi survives and multiplies intracellularly within human DC (78), and L. monocytogenes (30), B. bronchiseptica (29), and S. enterica subsp. enterica (23) apparently survive within the murine DC line CB1. Electron microscopy reveals both viable and degraded Chlamydia in murine DC (55, 75) and both viable and degraded B. burgdorferi in human DC (21). Further, murine DC, collected after in vivo infection with L. major, contained viable parasites that caused the development of lesions upon reinjection into BALB/c mice (51).

Although the murine DC line tsDC kills M. tuberculosis (76), these bacteria grow more rapidly within human DC than in human M[var phi] (22). Most interesting is the fact that IL-10, but not IFN-γ, TNF-α, IFN-γ in combination with TNF-α, IL-4, or transforming growth factor β, significantly suppresses the growth of M. tuberculosis in DC but not in M[var phi] (22). Thus, it is clear that the interactions of DC with microorganisms vary both with the species of DC and with the particular microorganism under investigation.

Although killing of a microorganism would seem to be a necessary prerequisite to obtain efficient presentation of antigens, Moll and colleagues (51) found that murine DC contained viable, virulent L. major parasites, but infected DC still were capable of stimulating lymphocyte proliferation. Because the DC that stimulated proliferation contained viable organisms, possibly a small number of intracellular parasites were actually degraded and antigen was processed and deposited on the surface of the infected DC prior to presentation to lymphocytes. Alternatively, antigens could be processed and regurgitated by other infected phagocytes and then transferred to DC for presentation. However, attempts to demonstrate that mycobacterial antigens could be transferred from infected M[var phi] to DC were unsuccessful (58). Whether DC might acquire antigens from other microbial pathogens via this route remains to be determined.

Lastly, we demonstrated that phagocytosis of both viable and HK Candida cells by human DC leads to the stimulation of T-cell proliferation. As we found in our studies of human DC and H. capsulatum (24), DC that had phagocytosed viable Candida cells actually were more efficient at stimulating T-cell proliferation than DC that had ingested HK cells. Thus, ingestion of 1,000-fold fewer viable yeast cells than HK cells led to equivalent stimulation of lymphocyte proliferation. These results are in agreement with the fact that mice develop better immunity when given a sublethal inoculum of a viable organism than they do with HK organisms. Thus, these data again suggest that the heat-inactivation process may destroy important immunogenic antigens and have implications for the design and use of DC in vaccine strategies.

Although we did not skin test our donors for sensitivity to Candida antigens, we presume that the proliferation observed was mostly a secondary response, as C. albicans is a commensal organism in humans. Likewise, in our other studies with H. capsulatum and human DC (24) we presumed that the T-cell proliferation was a secondary response, as Histoplasma is indigenous in Cincinnati. In those studies, we did identify three individuals whose T cells did not proliferate in an in vitro assay that utilized mixed mononuclear cells and HK cells as an in vitro correlate of a skin test. However, Histoplasma-infected DC from these three individuals did stimulate T-cell proliferation, demonstrating that human DC could stimulate T cells in a primary response. Further studies with naive (CD45RO-negative) and memory (CD45RO-positive) T cells will be required to determine if human DC stimulate both a primary and a secondary response upon ingestion of Candida.

d'Ostiani et al. (19) also reported that Candida-infected murine DC (FSDC and splenic DC) stimulated the proliferation of T cells. However, proliferation was not obtained with the mixture of DC, Candida, and T cells as reported here. In that system, Candida-pulsed DC and T cells first were cultured for 5 days in the presence of IL-2. Subsequently, the primed T cells were restimulated for 4 more days with fresh APC (irradiated, T-cell-depleted splenocytes), heat-inactivated Candida, and IL-2 before quantitation of lymphoproliferation.

The most likely explanation for the difference in the results between these two studies is the fact that C. albicans is not a commensal organism in mice. Thus, it would appear that in vitro murine DC could not stimulate T-cell proliferation in a primary response even in the presence of IL-2. We hypothesize that after immature human DC phagocytose Candida they differentiate into mature DC with potent APC activity. In contrast, at least in vitro, murine FSDC and splenic DC apparently did not differentiate into mature APC. The only other reports that DC stimulated lymphocyte proliferation after phagocytosis of a viable microbial pathogen were with L. major (39, 51), B. burgdorferi (21), and H. capsulatum (24).

There now is considerable evidence that DC play a key role in the host defense against infections by bridging the gap between innate immunity and CMI (12, 57, 62, 73). Our data provide evidence that human DC may act early in Candida infection through uptake, processing, and presentation of antigenic material to T cells. A greater understanding of the interaction of DC with pathogenic microorganisms will not only offer insights into pathogenesis but will also provide unique strategies for the future development of immunotherapies.

ACKNOWLEDGMENTS

This work was supported by Public Health Service grants AI-37639 and HL-55948 from the National Institutes of Health.

We thank Randal E. Morris and Georgianne Ciraolo for technical assistance with electron microscopy and Dan Marmer for technical assistance with flow cytometry.

REFERENCES

1. Ahuja S S, Mummidi S, Malech H L, Ahuja S K. Human dendritic cell (DC)-based anti-infective therapy: engineering DCs to secrete functional IFN-gamma and IL-12. J Immunol. 1998;161:868–876. [Abstract] [Google Scholar]
2. Anaissie E J, Rex J H, Uzun O, Vartivarian S. Predictors of adverse outcome in cancer patients with candidemia. Am J Med. 1998;104:238–245. [Abstract] [Google Scholar]
3. Ashman R B, Papadimitriou J M. Production and function of cytokines in natural and acquired immunity to Candida albicans infection. Microbiol Rev. 1995;59:646–672. [Europe PMC free article] [Abstract] [Google Scholar]
4. Austyn J M. Antigen uptake and presentation by dendritic leukocytes. Semin Immunol. 1992;4:227–236. [Abstract] [Google Scholar]
5. Austyn J M. New insights into the mobilization and phagocytic activity of dendritic cells. J Exp Med. 1996;183:1287–1292. [Europe PMC free article] [Abstract] [Google Scholar]
6. Avrameas A, McIlroy D, Hosmalin A, Autran B, Debre P, Monsigny M, Roche A C, Midoux P. Expression of a mannose/fucose membrane lectin on human dendritic cells. Eur J Immunol. 1996;26:394–400. [Abstract] [Google Scholar]
7. Bender A, Albert M, Reddy A, Feldman M, Sauter B, Kaplan G, Hellman W, Bhardwaj N. The distinctive features of influenza virus infection of dendritic cells. Immunobiology. 1998;198:552–567. [Abstract] [Google Scholar]
8. Blank C, Fuchs H, Rappersberger K, Rollinghoff M, Moll H. Parasitism of epidermal Langerhans cells in experimental cutaneous leishmaniasis with Leishmania major. J Infect Dis. 1993;167:418–425. [Abstract] [Google Scholar]
9. Butler K M, Baker C J. Candida: an increasingly important pathogen in the nursery. Pediatr Clin North Am. 1988;35:543–563. [Abstract] [Google Scholar]
10. Cenci E, Mencacci A, Spaccapelo R, Tonnetti L, Mosci P, Enssle K H, Puccetti P, Romani L, Bistoni F. T helper cell type 1 (Th1)- and Th2-like responses are present in mice with gastric candidiasis but protective immunity is associated with Th1 development. J Infect Dis. 1995;171:1279–1288. [Abstract] [Google Scholar]
11. Cenci E, Romani L, Vecchiarelli A, Puccetti P, Bistoni F. T cell subsets and IFN-gamma production in resistance to systemic candidosis in immunized mice. J Immunol. 1990;144:4333–4339. [Abstract] [Google Scholar]
12. Clark G J, Angel N, Kato M, Lopez J A, MacDonald K, Vuckovic S, Hart D N. The role of dendritic cells in the innate immune system. Microbes Infect. 2000;2:257–272. [Abstract] [Google Scholar]
13. Condaminet B, Peguet-Navarro J, Stahl P D, Dalbiez-Gauthier C, Schmitt D, Berthier-Vergnes O. Human epidermal Langerhans cells express the mannose-fucose binding receptor. Eur J Immunol. 1998;28:3541–3551. [Abstract] [Google Scholar]
14. Cumberbatch M, Kimber I. Dermal tumour necrosis factor-alpha induces dendritic cell migration to draining lymph nodes, and possibly provides one stimulus for Langerhans' cell migration. Immunology. 1992;75:257–263. [Abstract] [Google Scholar]
15. Dean D A, Burchard K W. Surgical perspective on invasive Candida infections. World J Surg. 1998;22:127–134. [Abstract] [Google Scholar]
16. Diamond R D, Clark R A, Haudenschild C C. Damage to Candida albicans hyphae and pseudohyphae by the myeloperoxidase system and oxidative products of neutrophil metabolism in vitro. J Clin Investig. 1980;66:908–917. [Europe PMC free article] [Abstract] [Google Scholar]
17. Diamond R D, Haudenschild C C. Monocyte-mediated serum-independent damage to hyphal and pseudohyphal forms of Candida albicans in vitro. J Clin Investig. 1981;67:173–182. [Europe PMC free article] [Abstract] [Google Scholar]
18. Domer J E, Carrow E W. Candidiasis. In: Cox R A, editor. Immunology of fungal diseases. Boca Raton, Fla: CRC Press; 1989. pp. 57–92. [Google Scholar]
19. d'Ostiani C F, Del Sero G, Bacci A, Montagnoli C, Spreca A, Mencacci A, Ricciardi-Castagnoli P, Romani L. Dendritic cells discriminate between yeasts and hyphae of the fungus Candida albicans. Implications for initiation of T helper cell immunity in vitro and in vivo. J Exp Med. 2000;191:1661–1674. [Europe PMC free article] [Abstract] [Google Scholar]
20. Dromer F, Improvisi L, Dupont B, Eliaszewicz M, Pialoux G, Fournier S, Feuillie V. Oral transmission of Candida albicans between partners in HIV-infected couples could contribute to dissemination of fluconazole-resistant isolates. AIDS. 1997;11:1095–1101. [Abstract] [Google Scholar]
21. Filgueira L, Nestle F O, Rittig M, Joller H I, Groscurth P. Human dendritic cells phagocytose and process Borrelia burgdorferi. J Immunol. 1996;157:2998–3005. [Abstract] [Google Scholar]
22. Fortsch D, Rollinghoff M, Stenger S. IL-10 converts human dendritic cells into macrophage-like cells with increased antibacterial activity against virulent Mycobacterium tuberculosis. J Immunol. 2000;165:978–987. [Abstract] [Google Scholar]
23. Garcia-Del Portillo F, Jungnitz H, Rohde M, Guzman C A. Interaction of Salmonella enterica serotype Typhimurium with dendritic cells is defined by targeting to compartments lacking lysosomal membrane glycoproteins. Infect Immun. 2000;68:2985–2991. [Europe PMC free article] [Abstract] [Google Scholar]
24. Gildea L A, Morris R E, Newman S L. Histoplasma capsulatum yeasts are phagocytosed via very late antigen-5, killed, and processed for antigen presentation by human dendritic cells. J Immunol. 2001;166:1049–1056. [Abstract] [Google Scholar]
25. Gorak P M, Engwerda C R, Kaye P M. Dendritic cells, but not macrophages, produce IL-12 immediately following Leishmania donovani infection. Eur J Immunol. 1998;28:687–695. [Abstract] [Google Scholar]
26. Greenfield R A. Host defense system interactions with Candida. J Med Vet Mycol. 1992;30:89–104. [Abstract] [Google Scholar]
27. Grosjean I, Caux C, Bella C, Berger I, Wild F, Banchereau J, Kaiserlian D. Measles virus infects human dendritic cells and blocks their allostimulatory properties for CD4+ T cells. J Exp Med. 1997;186:801–812. [Europe PMC free article] [Abstract] [Google Scholar]
28. Guggenheimer J, Moore P A, Rossie K, Myers D, Mongelluzzo M B, Block H M, Weyant R, Orchard T. Insulin-dependent diabetes mellitus and oral soft tissue pathologies. II. Prevalence and characteristics of Candida and Candidal lesions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000;89:570–576. [Abstract] [Google Scholar]
29. Guzman C A, Rohde M, Bock M, Timmis K N. Invasion and intracellular survival of Bordetella bronchiseptica in mouse dendritic cells. Infect Immun. 1994;62:5528–5537. [Europe PMC free article] [Abstract] [Google Scholar]
30. Guzman C A, Rohde M, Chakraborty T, Domann E, Hudel M, Wehland J, Timmis K N. Interaction of Listeria monocytogenes with mouse dendritic cells. Infect Immun. 1995;63:3665–3673. [Europe PMC free article] [Abstract] [Google Scholar]
31. Guzman C A, Rohde M, Timmis K N. Mechanisms involved in uptake of Bordetella bronchiseptica by mouse dendritic cells. Infect Immun. 1994;62:5538–5544. [Europe PMC free article] [Abstract] [Google Scholar]
32. Henderson R A, Watkins S C, Flynn J L. Activation of human dendritic cells following infection with Mycobacterium tuberculosis. J Immunol. 1997;159:635–643. [Abstract] [Google Scholar]
33. Holmstrup P, Samaranayake L P. Acute and AIDS-related oral candidosis. In: Smaranayake L P, MacFarlane T W, editors. Oral candidosis. London, England: Wright; 1990. pp. 133–155. [Google Scholar]
34. Huang Y C, Lin T Y, Lien R I, Chou Y H, Kuo C Y, Yang P H, Hsieh W S. Candidaemia in special care nurseries: comparison of albicans and parapsilosis infection. J Infect. 2000;40:171–175. [Abstract] [Google Scholar]
35. Inaba K, Inaba M, Naito M, Steinman R M. Dendritic cell progenitors phagocytose particulates, including bacillus Calmette-Guerin organisms, and sensitize mice to mycobacterial antigens in vivo. J Exp Med. 1993;178:479–488. [Europe PMC free article] [Abstract] [Google Scholar]
36. Johnston R B, Jr, Keele B B, Jr, Misra H P, Webb L S, Lehmeyer J E, RaJagopalan K V. Superoxide anion generation and phagocytic bactericidal activity. In: Bellanti J A, Dayton D H, editors. The phagocytic cell in host resistance. New York, N.Y: Raven Press; 1975. pp. 61–75. [Europe PMC free article] [Abstract] [Google Scholar]
37. Kitz D J, Stahl P D, Little J R. The effect of a mannose binding protein on macrophage interactions with Candida albicans. Cell Mol Biol. 1992;38:407–412. [Abstract] [Google Scholar]
38. Kolb-Maurer A, Gentschev I, Fries H W, Fiedler F, Brocker E B, Kampgen E, Goebel W. Listeria monocytogenes-infected human dendritic cells: uptake and host cell response. Infect Immun. 2000;68:3680–3688. [Europe PMC free article] [Abstract] [Google Scholar]
39. Konecny P, Stagg A J, Jebbari H, English N, Davidson R N, Knight S C. Murine dendritic cells internalize Leishmania major promastigotes, produce IL-12 p40 and stimulate primary T cell proliferation in vitro. Eur J Immunol. 1999;29:1803–1811. [Abstract] [Google Scholar]
40. Kozel T R, Brown R R, Pfrommer G S. Activation and binding of C3 by Candida albicans. Infect Immun. 1987;55:1890–1894. [Europe PMC free article] [Abstract] [Google Scholar]
41. Kubes P, Kanwar S, Niu X F, Gaboury J P. Nitric oxide synthesis inhibition induces leukocyte adhesion via superoxide and mast cells. FASEB J. 1993;7:1293–1299. [Abstract] [Google Scholar]
42. Larsen C P, Steinman R M, Witmer-Pack M, Hankins D F, Morris P J, Austyn J M. Migration and maturation of Langerhans cells in skin transplants and explants. J Exp Med. 1990;172:1483–1493. [Europe PMC free article] [Abstract] [Google Scholar]
43. Larsson M, Majeed M, Ernst J D, Magnusson K E, Stendahl O, Forsum U. Role of annexins in endocytosis of antigens in immature human dendritic cells. Immunology. 1997;92:501–511. [Abstract] [Google Scholar]
44. Lehrer R I. The fungicidal mechanisms of human monocytes. I. Evidence for myeloperoxidase-linked and myeloperoxidase-independent candidacidal mechanisms. J Clin Investig. 1975;55:338–346. [Europe PMC free article] [Abstract] [Google Scholar]
45. Marcus J, Grossman M E, Yunakov M J, Rappaport F. Disseminated candidiasis, Candida arthritis, and unilateral skin lesions. J Am Acad Dermatol. 1992;26:295–297. [Abstract] [Google Scholar]
46. Marodi L. Local and systemic host defense mechanisms against Candida: immunopathology of candidal infections. Pediatr Infect Dis J. 1997;16:795–801. [Abstract] [Google Scholar]
47. Marodi L, Korchak H M, Johnston R B., Jr Mechanisms of host defense against Candida species. I. Phagocytosis by monocytes and monocyte-derived macrophages. J Immunol. 1991;146:2783–2789. [Abstract] [Google Scholar]
48. Mencacci A, Cenci E, Del Sero G, Fe d'Ostiani C, Mosci P, Trinchieri G, Adorini L, Romani L. IL-10 is required for development of protective Th1 responses in IL-12-deficient mice upon Candida albicans infection. J Immunol. 1998;161:6228–6237. [Abstract] [Google Scholar]
49. Mencacci A, Del Sero G, Cenci E, d'Ostiani C F, Bacci A, Montagnoli C, Kopf M, Romani L. Endogenous interleukin 4 is required for development of protective CD4+ T helper type 1 cell responses to Candida albicans. J Exp Med. 1998;187:307–317. [Europe PMC free article] [Abstract] [Google Scholar]
50. Moll H, Flohe S, Rollinghoff M. Dendritic cells in Leishmania major-immune mice harbor persistent parasites and mediate an antigen-specific T cell immune response. Eur J Immunol. 1995;25:693–699. [Abstract] [Google Scholar]
51. Moll H, Fuchs H, Blank C, Rollinghoff M. Langerhans cells transport Leishmania major from the infected skin to the draining lymph node for presentation to antigen-specific T cells. Eur J Immunol. 1993;23:1595–1601. [Abstract] [Google Scholar]
52. Newman S L, Bucher C, Rhodes J, Bullock W E. Phagocytosis of Histoplasma capsulatum yeasts and microconidia by human cultured macrophages and alveolar macrophages. Cellular cytoskeleton requirement for attachment and ingestion. J Clin Investig. 1990;85:223–230. [Europe PMC free article] [Abstract] [Google Scholar]
53. Newman S L, Gootee L, Kidd C, Ciraolo G M, Morris R. Activation of human macrophage fungistatic activity against Histoplasma capsulatum upon adherence to type 1 collagen matrices. J Immunol. 1997;158:1779–1786. [Abstract] [Google Scholar]
54. O'Doherty U, Steinman R M, Peng M, Cameron P U, Gezelter S, Kopeloff I, Swiggard W J, Pope M, Bhardwaj N. Dendritic cells freshly isolated from human blood express CD4 and mature into typical immunostimulatory dendritic cells after culture in monocyte-conditioned medium. J Exp Med. 1993;178:1067–1076. [Europe PMC free article] [Abstract] [Google Scholar]
55. Ojcius D M, Bravo de Alba Y, Kanellopoulos J M, Hawkins R A, Kelly K A, Rank R G, Dautry-Varsat A. Internalization of Chlamydia by dendritic cells and stimulation of Chlamydia-specific T cells. J Immunol. 1998;160:1297–1303. [Abstract] [Google Scholar]
56. Olken N M, Rusche K M, Richards M K, Marletta M A. Inactivation of macrophage nitric oxide synthase activity by NG-methyl-l-arginine. Biochem Biophys Res Commun. 1991;177:828–833. [Abstract] [Google Scholar]
57. Palucka K, Banchereau J. Dendritic cells: a link between innate and adaptive immunity. J Clin Immunol. 1999;19:12–25. [Abstract] [Google Scholar]
58. Pancholi P, Mirza A, Schauf V, Steinman R M, Bhardwaj N. Presentation of mycobacterial antigens by human dendritic cells: lack of transfer from infected macrophages. Infect Immun. 1993;61:5326–5332. [Europe PMC free article] [Abstract] [Google Scholar]
59. Phair J, Munoz A, Detels R, Kaslow R, Rinaldo C, Saah A. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N Engl J Med. 1990;322:161–165. [Abstract] [Google Scholar]
60. Puccetti P, Mencacci A, Cenci E, Spaccapelo R, Mosci P, Enssle K H, Romani L, Bistoni F. Cure of murine candidiasis by recombinant soluble interleukin-4 receptor. J Infect Dis. 1994;169:1325–1331. [Abstract] [Google Scholar]
61. Rantala A. Postoperative candidiasis. Ann Chir Gynaecol Suppl. 1993;205:1–52. [Abstract] [Google Scholar]
62. Reis e Sousa C, Sher A, Kaye P. The role of dendritic cells in the induction and regulation of immunity to microbial infection. Curr Opin Immunol. 1999;11:392–399. [Abstract] [Google Scholar]
63. Roake J A, Rao A S, Morris P J, Larsen C P, Hankins D F, Austyn J M. Dendritic cell loss from nonlymphoid tissues after systemic administration of lipopolysaccharide, tumor necrosis factor, and interleukin 1. J Exp Med. 1995;181:2237–2247. [Europe PMC free article] [Abstract] [Google Scholar]
64. Romani L, Cenci E, Mencacci A, Spaccapelo R, Grohmann U, Puccetti P, Bistoni F. Gamma interferon modifies CD4+ subset expression in murine candidiasis. Infect Immun. 1992;60:4950–4952. [Europe PMC free article] [Abstract] [Google Scholar]
65. Romani L, Mencacci A, Cenci E, Spaccapelo R, Mosci P, Puccetti P, Bistoni F. CD4+ subset expression in murine candidiasis. Th responses correlate directly with genetically determined susceptibility or vaccine-induced resistance. J Immunol. 1993;150:925–931. [Abstract] [Google Scholar]
66. Romani L, Mencacci A, Cenci E, Spaccapelo R, Toniatti C, Puccetti P, Bistoni F, Poli V. Impaired neutrophil response and CD4+ T helper cell 1 development in interleukin 6-deficient mice infected with Candida albicans. J Exp Med. 1996;183:1345–1355. [Europe PMC free article] [Abstract] [Google Scholar]
67. Romani L, Mencacci A, Grohmann U, Mocci S, Mosci P, Puccetti P, Bistoni F. Neutralizing antibody to interleukin 4 induces systemic protection and T helper type 1-associated immunity in murine candidiasis. J Exp Med. 1992;176:19–25. [Europe PMC free article] [Abstract] [Google Scholar]
68. Romani N, Schuler G. The immunologic properties of epidermal Langerhans cells as a part of the dendritic cell system. Semin Immunopathol. 1992;13:265–279. [Abstract] [Google Scholar]
69. Schnur R A, Newman S L. The respiratory burst response to Histoplasma capsulatum by human neutrophils. Evidence for intracellular trapping of superoxide anion. J Immunol. 1990;144:4765–4772. [Abstract] [Google Scholar]
70. Steinman R M. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 1991;9:271–296. [Abstract] [Google Scholar]
71. Steinman R M, Adams J C, Cohn Z A. Identification of a novel cell type in peripheral lymphoid organs of mice. IV. Identification and distribution in mouse spleen. J Exp Med. 1975;141:804–820. [Europe PMC free article] [Abstract] [Google Scholar]
72. Steinman R M, Cohn Z A. Identification of a novel cell type in peripheral lymphoid organs of mice. II. Functional properties in vitro. J Exp Med. 1974;139:380–397. [Europe PMC free article] [Abstract] [Google Scholar]
73. Stockwin L H, McGonagle D, Martin I G, Blair G E. Dendritic cells: immunological sentinels with a central role in health and disease. Immunol Cell Biol. 2000;78:91–102. [Europe PMC free article] [Abstract] [Google Scholar]
74. Stuehr D J, Fasehun O A, Kwon N S, Gross S S, Gonzalez J A, Levi R, Nathan C F. Inhibition of macrophage and endothelial cell nitric oxide synthase by diphenyleneiodonium and its analogs. FASEB J. 1991;5:98–103. [Abstract] [Google Scholar]
75. Su H, Messer R, Whitmire W, Fischer E, Portis J C, Caldwell H D. Vaccination against chlamydial genital tract infection after immunization with dendritic cells pulsed ex vivo with nonviable chlamydiae. J Exp Med. 1998;188:809–818. [Europe PMC free article] [Abstract] [Google Scholar]
76. Tascon R E, Soares C S, Ragno S, Stavropoulos E, Hirst E M, Colston M J. Mycobacterium tuberculosis-activated dendritic cells induce protective immunity in mice. Immunology. 2000;99:473–480. [Abstract] [Google Scholar]
77. Thompson H L, Wilton J M. Interaction and intracellular killing of Candida albicans blastospores by human polymorphonuclear leucocytes, monocytes and monocyte-derived macrophages in aerobic and anaerobic conditions. Clin Exp Immunol. 1992;87:316–321. [Abstract] [Google Scholar]
78. Van Overtvelt L, Vanderheyde N, Verhasselt V, Ismaili J, De Vos L, Goldman M, Willems F, Vray B. Trypanosoma cruzi infects human dendritic cells and prevents their maturation: inhibition of cytokines, HLA-DR, and costimulatory molecules. Infect Immun. 1999;67:4033–4040. [Europe PMC free article] [Abstract] [Google Scholar]
79. Verduyn Lunel F M, Meis J F, Voss A. Nosocomial fungal infections: candidemia. Diagn Microbiol Infect Dis. 1999;34:213–220. [Abstract] [Google Scholar]
80. von Stebut E, Belkaid Y, Jakob T, Sacks D L, Udey M C. Uptake of Leishmania major amastigotes results in activation and interleukin 12 release from murine skin-derived dendritic cells: implications for the initiation of anti-Leishmania immunity. J Exp Med. 1998;188:1547–1552. [Europe PMC free article] [Abstract] [Google Scholar]
81. Wagner D K, Collins-Lech C, Sohnle P G. Inhibition of neutrophil killing of Candida albicans pseudohyphae by substances which quench hypochlorous acid and chloramines. Infect Immun. 1986;51:731–735. [Europe PMC free article] [Abstract] [Google Scholar]
82. Wenzel R P, Pfaller M A. Candida species: emerging hospital bloodstream pathogens. Infect Control Hosp Epidemiol. 1991;12:523–524. [Abstract] [Google Scholar]
83. Will A, Blank C, Rollinghoff M, Moll H. Murine epidermal Langerhans cells are potent stimulators of an antigen-specific T cell response to Leishmania major, the cause of cutaneous leishmaniasis. Eur J Immunol. 1992;22:1341–1347. [Abstract] [Google Scholar]
84. Witmer-Pack M D, Crowley M T, Inaba K, Steinman R M. Macrophages, but not dendritic cells, accumulate colloidal carbon following administration in situ. J Cell Sci. 1993;105:965–973. [Abstract] [Google Scholar]
85. Zhang M X, Kozel T R. Mannan-specific immunoglobulin G antibodies in normal human serum accelerate binding of C3 to Candida albicans via the alternative complement pathway. Infect Immun. 1998;66:4845–4850. [Europe PMC free article] [Abstract] [Google Scholar]
86. Zhang M X, Lupan D M, Kozel T R. Mannan-specific immunoglobulin G antibodies in normal human serum mediate classical pathway initiation of C3 binding to Candida albicans. Infect Immun. 1997;65:3822–3827. [Europe PMC free article] [Abstract] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

Citations & impact 


Impact metrics

Jump to Citations

Citations of article over time

Article citations


Go to all (82) article citations

Funding 


Funders who supported this work.

NHLBI NIH HHS (1)

NIAID NIH HHS (1)